Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EFPIA Calls On Drug Firms To Embrace Multi HTA Early Dialogue Scheme

This article was originally published in The Pink Sheet Daily

Executive Summary

EFPIA is calling on its members to sign up to the European Commission’s multi HTA early dialogue initiative to harmonize some significant aspects of European reimbursement.

You may also be interested in...



Lilly Rejects NICE Comparator For Efient In ACS, But Gains Approval Anyway

Despite Lilly's decision not to make an indirect comparison its chosen comparator, AstraZeneca’s Brilinta, NICE agrees that Lilly's Efient is cost-effective and sometimes clinically superior to standard care.

Divergent Standard Care Makes Full EU Regulator/HTA Harmony Unlikely

While EU regulators and HTA bodies are coming together on major drug development criteria, differing standard care regimes across the 28 European Union member states makes real harmonization seem far off.

EU Regulators/HTAs Alliance Lacks Specifics On Trial Comparators

Agreement between Europe’s regulators and HTA bodies to develop collaborative approach does not yet address fundamental issues, such as standardization of comparator selection.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel